No black box warning on record for Braftovi

As of the latest FDA labeling reviewed, Braftovi (ENCORAFENIB) does not carry a black box warning. Standard warnings and precautions still apply — see the full Braftovi medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • New Primary Malignancies, cutaneous and noncutaneous : Can occur. Monitor for malignancies and perform dermatologic evaluations prior to, while on therapy, and following discontinuation of treatment. ( 5.1 ) • Tumor Promotion in BRAF Wild-Type Tumors : Increased cell proliferation can occur with BRAF inhibitors. ( 5.2 ) • Cardiomyopathy : Assess left ventricular ejecti

No black box warning on record for Braftovi

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • New Primary Malignancies, cutaneous and noncutaneous : Can occur. Monitor for malignancies and perform dermatologic evaluations prior to, while on therapy, and following discontinuation of treatment. ( 5.1 ) • Tumor Promotion in BRAF Wild-Type Tumors : Increased cell proliferation can occur with BRAF inhibitors. ( 5.2 ) • Cardiomyopathy : Assess left ventricular ejecti

Braftovi Black Box Warning

No black box warning on record for Braftovi

Other warnings & precautions

Braftovi Black Box Warning

No black box warning on record for Braftovi

Other warnings & precautions